Dr. Margaret Callahan is the Immunotherapeutics Program Research Director and medical oncologist at Memorial Sloan Kettering Cancer Center. She is one of the two study chairs of the clinical trial “A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab” (NCT01975831).
This study examines combinations of two checkpoint immunotherapies, in patients diagnosed with breast cancer, cervical cancer, colorectal cancer, kidney cancer, and ovarian cancer. One checkpoint inhibitor, durvalumab (Imfinzi™), blocks the PD-L1 pathway, whereas the other, tremelimumab, blocks the CTLA-4 pathway.
Additional investigators working on this trial include:
- Antoni Ribas, M.D., Ph.D., University of California, Los Angeles
- Jedd D. Wolchok, M.D., Ph.D., Memorial Sloan Kettering Cancer Center (Other study chair)
- Kunle Odunsi, M.D., UChicago Medicine Comprehensive Cancer Center
- Mario Sznol, M.D., Yale University
- Patrick Dillon M.D., University Virginia Health
- Patrick Ott, M.D., Dana Farber Cancer Institute
- Reva Schneider, M.D., Mary Crowley Cancer Center
Projects and Grants
A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab (NCT01975831)
Memorial Sloan Kettering Cancer Center | Breast Cancer, Cervical Cancer, Colorectal Cancer, Kidney Cancer, Ovarian Cancer | 2013
Let's spread the word about Immunotherapy! Click to share this page with your community.